

January 21, 2025



Poxel: Ordinary and Extraordinary General Meeting to Be Held on February 11, 2025

- Poxel announces that a Combined General Meeting will be held on February 11, 2025, at 9:00 a.m. CET and the availability of the preparatory documents
- Poxel announces the addition of a new resolution to the agenda in connection with the alert procedure of the statutory auditors in response to the significant uncertainty over the Company's business continuity resulting from the non-adoption of the financial resolutions at the Combined General Meeting held on November 28, 2024

LYON, France--(BUSINESS WIRE)-- Regulatory News:

[POXEL SA](#) (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, today informs its shareholders that a Combined General Meeting will be held on February 11, 2025, at 9:00 am CET at the Mercure Lyon Centre Château Perrache Hotel, located at 12 Cours de Verdun-Rambaud Esplanade de la Gare, 69002 Lyon, and provides information on voting procedures.

Following a decision by the Board of Directors on January 20, 2025, a specific resolution has been added to the agenda of the Combined General Meeting, in connection with the alert procedure initiated by the statutory auditors in response to the significant uncertainty over the Company's business continuity resulting from the non-adoption of the financial resolutions at the Combined General Meeting of November 28, 2024. Shareholders are now invited to deliberate on the Company's situation in accordance with the provisions of article L. 234-1 of the French Commercial Code. The new resolution is included in the preparatory documents available to shareholders, and in the convening notice as published in the BALO (French legal gazette) on January 24, 2025.

All preparatory documents and information related to this General Meeting are available to shareholders under legal and regulatory conditions and can be accessed on the [Company's website](#) in the "Annual General Meeting Documents" section.

In accordance with current regulations, Poxel shareholders may cast their votes before the General Meeting, starting from January 24, 2025, by mail, proxy, or electronically, following the instructions in the meeting notice published in the BALO on January 6, 2025, and reproduced in the convening notice.

The option to vote or grant proxy electronically is available via the **secure voting platform**

Votacess, which will open on January 24, 2025, at 9:00 am (Paris time) and close on February 10, 2025, at 3:00 pm (Paris time).

Voting instructions are also detailed in the practical guide available to shareholders on the [Company's website](#).

For any questions regarding voting procedures, you may contact the Investor Relations team by email: investors@poxelpharma.com.

Shareholders willing to follow the General Meeting but unable to attend in person are invited to connect via the following link (*the General Meeting will be held in French*): [click here](#).

This live broadcast of the General Meeting will not allow remote voting or questions via the chat feature on the platform used.

A replay of the General Meeting will be available on the Company's website after the meeting.

About Poxel SA

Poxel is a **clinical stage biopharmaceutical company** developing **innovative treatments for chronic serious diseases with metabolic pathophysiology**, including **metabolic dysfunction-associated steatohepatitis (MASH)** and rare disorders. For the treatment of MASH, **PXL065** (deuterium-stabilized *R*-pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of **PXL770**, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). **TWYMEEG[®]** (Imeglimin), Poxel's first-in-class product that targets mitochondrial dysfunction, is now marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.

For more information, please visit: www.poxelpharma.com

All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements. The Company does not endorse or is not otherwise responsible for the content of external hyperlinks referred to in this press release.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20250121241201/en/>

Contacts - Investor relations / Media

NewCap

Nicolas Fossiez, Aurélie Manavarere / Arthur Rouillé

investors@poxelpharma.com

+33 1 44 71 94 94

Source: Poxel